Christopher Power

List of Publications by Year
in descending order

235	17,204	14655 66	17105 122
papers	citations	h-index	g-index

240	240	240	16416
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metalloproteinases in biology and pathology of the nervous system. Nature Reviews Neuroscience, 2001, 2, 502-511.	10.2	946
2	Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1. Journal of Biological Chemistry, 2001, 276, 43503-43508.	3.4	576
3	Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3117-3121.	7.1	552
4	Inflammasomes in the CNS. Nature Reviews Neuroscience, 2014, 15, 84-97.	10.2	537
5	The promise of minocycline in neurology. Lancet Neurology, The, 2004, 3, 744-751.	10.2	465
6	Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dememtia. Annals of Neurology, 1993, 33, 576-582.	5.3	444
7	Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6065-E6074.	7.1	346
8	Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood-brain barrier. Annals of Neurology, 1993, 34, 339-350.	5.3	345
9	Human endogenous retrovirus glycoproteinâ€“mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nature Neuroscience, 2004, 7, 1088-1095.	14.8	343
10	Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Annals of Neurology, 2003, 53, 731-742.	5.3	334
11	HIV Dementia Scale: A Rapid Screening Test. Journal of Acquired Immune Deficiency Syndromes, 1995, 8, 273-278.	0.3	302
12	A1 Adenosine Receptor Upregulation and Activation Attenuates Neuroinflammation and Demyelination in a Model of Multiple Sclerosis. Journal of Neuroscience, 2004, 24, 1521-1529.	3.6	297
13	HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nature Neuroscience, 2003, 6, 1064-1071.	14.8	295
14	Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. Journal of Virology, 1994, 68, 4643-4649.	3.4	268
15	Zika virus inhibits typeâ€‰interferon production and downstream signaling. EMBO Reports, 2016, 17, 1766-1775.	4.5	252
16	Interleukin-1? promotes oligodendrocyte death through glutamate excitotoxicity. Annals of Neurology, 2003, 53, 588-595.	5.3	228
17	The Tat Protein of HIV-1 Induces Tumor Necrosis Factor-Î± Production. Journal of Biological Chemistry, 1997, 272, 22385-22388.	3.4	208
18	Fiery Cell Death: Pyroptosis in the Central Nervous System. Trends in Neurosciences, 2020, 43, 55-73.	8.6	205

#	Article	IF	Citations
19	Impaired neurosteroid synthesis in multiple sclerosis. Brain, 2011, 134, 2703-2721.	7.6	192
20	Neurologic disease burden in treated HIV/AIDS predicts survival. Neurology, 2010, 75, 1150-1158.	1.1	189
21	Monocyte activation and differentiation augment human endogenous retrovirus expression: Implications for inflammatory brain diseases. Annals of Neurology, 2001, 50, 434-442.	5.3	186
22	Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. Retrovirology, 2014, 11, 35.	2.0	180
23	Neuronal Death Induced by Brain-Derived Human Immunodeficiency Virus Type 1 Envelope Genes Differs between Demented and Nondemented AIDS Patients. Journal of Virology, 1998, 72, 9045-9053.	3.4	170
24	Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology, 2004, 329, 302-318.	2.4	158
25	Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor-Î± Expression Is Neuroprotective After Intracerebral Hemorrhage. Stroke, 2001, 32, 240-248.	2.0	146
26	Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. Journal of Experimental Medicine, 2006, 203, 425-435.	8.5	145
27	Parkinsonism with HIV infection. Movement Disorders, 1998, 13, 684-689.	3.9	143
28	Autopsy Study of HIV-1â€“Positive and H IV-1â€“Negative Adult Medical Patients in Nairobi, Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 23-29.	2.1	141
29	Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Annals of Neurology, 2001, 49, 727-735.	5.3	138
30	Cytomegalovirus and Rasmussen's encephalitis. Lancet, The, 1990, 336, 1282-1284.	13.7	136
31	Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts. Brain, 2017, 140, 2273-2285.	7.6	134
32	Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitorÃ¢Â€Â“mediated neurotoxicity. Annals of Neurology, 2006, 59, 816-824.	5.3	131
33	HIV Infection of the Central Nervous System: Clinical Features and Neuropathogenesis. Neurologic Clinics, 2008, 26, 799-819.	1.8	127
34	Brain Microbial Populations in HIV/AIDS: Î±-Proteobacteria Predominate Independent of Host Immune Status. PLoS ONE, 2013, 8, e54673.	2.5	127
35	A model of human immunodeficiency virus encephalitis in scid mice.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8658-8662.	7.1	126
36	HIV-1 Vpr Causes Neuronal Apoptosis andIn VivoNeurodegeneration. Journal of Neuroscience, 2007, 27, 3703-3711.	3.6	126

#	Article	IF	Citations
37	HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Annals of Neurology, 2001, 49, 230-241.	5.3	125
38	Neuroinflammation and Endoplasmic Reticulum Stress Are Coregulated by Crocin To Prevent Demyelination and Neurodegeneration. Journal of Immunology, 2011, 187, 4788-4799.	0.8	125
39	Proteinase-activated receptors in the nervous system. Nature Reviews Neuroscience, 2003, 4, 981-990.	10.2	123
40	The Human Endogenous Retrovirus Envelope Glycoprotein, Syncytin-1, Regulates Neuroinflammation and Its Receptor Expression in Multiple Sclerosis: A Role for Endoplasmic Reticulum Chaperones in Astrocytes. Journal of Immunology, 2007, 179, 1210-1224.	0.8	123
41	Up-Regulation of Proteinase-Activated Receptor 1 Expression in Astrocytes During HIV Encephalitis. Journal of Immunology, 2003, 170, 2638-2646.	0.8	115
42	Aboriginals with multiple sclerosis. Neurology, 2001, 56, 317-323.	1.1	109
43	West Nile Virus-Induced Neuroinflammation: Glial Infection and Capsid Protein-Mediated Neurovirulence. Journal of Virology, 2007, 81, 10933-10949.	3.4	105
44	AIDS- and nonâ€“AIDS-related PML association with distinct p53 polymorphism. Neurology, 2000, 54, 743-743.	1.1	102
45	Human endogenous retroviruses and multiple sclerosis: Innocent bystanders or disease determinants?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 162-176.	3.8	101
46	Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain, 2021, 144, 3576-3588.	7.6	101
47	Lentivirus Infection in the Brain Induces Matrix Metalloproteinase Expression: Role of Envelope Diversity. Journal of Virology, 2000, 74, 7211-7220.	3.4	98
48	Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Annals of Neurology, 2001, 49, 650-658.	5.3	98
49	Proteolytic processing of SDF-1Â reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19182-19187.	7.1	97
50	HIV-1 Viral Protein R Activates NLRP3 Inflammasome in Microglia: implications for HIV-1 Associated Neuroinflammation. Journal of NeuroImmune Pharmacology, 2017, 12, 233-248.	4.1	97
51	Zika Virus Hijacks Stress Granule Proteins and Modulates the Host Stress Response. Journal of Virology, 2017, 91, .	3.4	96
52	Acute Disseminated Encephalomyelitis: Clinical and Pathogenesis Features. Neurologic Clinics, 2008, 26, 759-780.	1.8	95
53	MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis. Journal of Neuroinflammation, 2017, 14, 55.	7.2	95
54	Proteinase-Activated Receptor-2 Induction by Neuroinflammation Prevents Neuronal Death during HIV Infection. Journal of Immunology, 2005, 174, 7320-7329.	0.8	92

#	Article	IF	Citations
55	Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends in Neurosciences, 2009, 32, 88-100.	8.6	92
56	HIV-1 Associated Dementia: Clinical Features and Pathogenesis. Canadian Journal of Neurological Sciences, 1995, 22, 92-100.	0.5	91
57	Cadmium-induced IL-6 and IL-8 expression and release from astrocytes are mediated by MAPK and NF-Î¹B pathways. NeuroToxicology, 2017, 60, 82-91.	3.0	90
58	Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2019, 328, 50-59.	2.3	90
59	Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS. Neurology, 2009, 72, 835-841.	1.1	87
60	Regulation of neural cell survival by HIV-1 infection. Neurobiology of Disease, 2006, 21, 1-17.	4.4	85
61	Brain microbiota disruption within inflammatory demyelinating lesions in multiple sclerosis. Scientific Reports, 2016, 6, 37344.	3.3	85
62	Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Medicine, 2009, 10, 246-252.	2.2	80
63	Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Multiple Sclerosis Journal, 2014, 20, 1396-1400.	3.0	80
64	HIV-1 Tat Molecular Diversity and Induction of TNF-Î±: Implications for HIV-Induced Neurological Disease. NeuroImmunoModulation, 1998, 5, 184-192.	1.8	79
65	MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspaseâ€6 regulates astrocyte survival. FASEB Journal, 2010, 24, 1799-1812.	0.5	79
66	V3 Recombinants Indicate a Central Role for CCR5 as a Coreceptor in Tissue Infection by Human Immunodeficiency Virus Type 1. Journal of Virology, 1999, 73, 2350-2358.	3.4	75
67	Remission of Progressive Multifocal Leukoencephalopathy Following Splenectomy and Antiretroviral Therapy in a Patient with HIV Infection. New England Journal of Medicine, 1997, 336, 661-662.	27.0	71
68	Allopregnanolone and neuroinflammation: a focus on multiple sclerosis. Frontiers in Cellular Neuroscience, 2014, 8, 134.	3.7	71
69	Distinct HIV-1 env Sequences Are Associated with Neurotropism and Neurovirulence. Current Topics in Microbiology and Immunology, 1995, 202, 89-104.	1.1	69
70	Fatigue in HIV/AIDS is Associated With Depression and Subjective Neurocognitive Complaints but not Neuropsychological Functioning. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 201-215.	1.3	67
71	Hepatitis C Virus Core Protein Induces Neuroimmune Activation and Potentiates Human Immunodeficiency Virus-1 Neurotoxicity. PLoS ONE, 2010, 5, e12856.	2.5	66
72	Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. Journal of Neuroscience, 2016, 36, 10683-10695.	3.6	66

#	Article	IF	Citations
73	MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology. PLoS Pathogens, 2017, 13, e1006360.	4.7	65
74	Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Annals of Neurology, 1999, 45, 633-639.	5.3	62
75	Neurovirulence in Feline Immunodeficiency Virus-Infected Neonatal Cats Is Viral Strain Specific and Dependent on Systemic Immune Suppression. Journal of Virology, 1998, 72, 9109-9115.	3.4	62
76	Paroxysmal dyskinesias in patients with HIV infection. Neurology, 1999, 52, 109-109.	1.1	61
77	Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology, 2005, 334, 178-193.	2.4	61
78	Predictors of symptomatic <scp>HIV</scp>â€associated neurocognitive disorders in universal health care. HIV Medicine, 2013, 14, 99-107.	2.2	61
79	Growth hormone prevents human immunodeficiency virusâ€“induced neuronal p53 expression. Annals of Neurology, 2003, 54, 605-614.	5.3	60
80	MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation. Frontiers in Immunology, 2017, 8, 758.	4.8	60
81	HIVâ€1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. FASEB Journal, 2010, 24, 4343-4353.	0.5	59
82	Lentiviral Neuropathogenesis: Comparative Neuroinvasion, Neurotropism, Neurovirulence, and Host Neurosusceptibility. Journal of Virology, 2002, 76, 7923-7931.	3.4	58
83	Undetectable Cerebrospinal Fluid HIV RNA and Î²-2 Microglobulin Do Not Indicate Inactive AIDS Dementia Complex in Highly Active Antiretroviral Therapy-Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 426-429.	2.1	58
84	Comparative Expression of Human Endogenous Retrovirus-W Genes in Multiple Sclerosis. AIDS Research and Human Retroviruses, 2007, 23, 1251-1256.	1.1	58
85	Early Life Exposure to Lipopolysaccharide Suppresses Experimental Autoimmune Encephalomyelitis by Promoting Tolerogenic Dendritic Cells and Regulatory T Cells. Journal of Immunology, 2009, 183, 298-309.	0.8	58
86	Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients. Annals of Neurology, 1998, 44, 391-394.	5.3	57
87	Host MicroRNAs-221 and -222 Inhibit HIV-1 Entry in Macrophages by Targeting the CD4 Viral Receptor. Cell Reports, 2017, 21, 141-153.	6.4	57
88	Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. Retrovirology, 2017, 14, 47.	2.0	57
89	Progress in Clinical Neurosciences: The Neuropathogenesis of HIV Infection: Host-Virus Interaction and the Impact of Therapy. Canadian Journal of Neurological Sciences, 2002, 29, 19-32.	0.5	56
90	Productive Infection of Human Peripheral Blood Mononuclear Cells by Feline Immunodeficiency Virus: Implications for Vector Development. Journal of Virology, 1999, 73, 2491-2498.	3.4	56

#	Article	IF	Citations
91	Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. Journal of the Neurological Sciences, 2012, 312, 45-51.	0.6	55
92	Inflammasome induction in Rasmussenâ€™s encephalitis: cortical and associated white matter pathogenesis. Journal of Neuroinflammation, 2013, 10, 152.	7.2	55
93	NeuroAIDS: An Evolving Epidemic. Canadian Journal of Neurological Sciences, 2009, 36, 285-295.	0.5	54
94	Feline immunodeficiency virus causes increased glutamate levels and neuronal loss in brain. Neuroscience, 1997, 77, 1175-1185.	2.3	53
95	Proteinase-Activated Receptor-2 Exerts Protective and Pathogenic Cell Type-Specific Effects in Alzheimerâ€™s Disease. Journal of Immunology, 2007, 179, 5493-5503.	0.8	53
96	Brain-derived HIV-1 tat sequences from AIDS patients with dementia show increased molecular heterogeneity. Journal of NeuroVirology, 1998, 4, 387-393.	2.1	52
97	Primary Headaches in HIV-Infected Patients. Headache, 1999, 39, 3-10.	3.9	51
98	Bacterial Peptidoglycan as a Driver of Chronic Brain Inflammation. Trends in Molecular Medicine, 2020, 26, 670-682.	6.7	49
99	Human Immunodeficiency Virus Type 1 Envelope-Mediated Neuronal Death: Uncoupling of Viral Replication and Neurotoxicity. Journal of Virology, 2003, 77, 6899-6912.	3.4	48
100	HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. Aids, 2001, 15, 747-751.	2.2	47
101	Peripheral neuropathy in lentivirus infection. Aids, 2004, 18, 1241-1250.	2.2	47
102	Human Fetal Astrocytes Infected with Zika Virus Exhibit Delayed Apoptosis and Resistance to Interferon: Implications for Persistence. Viruses, 2018, 10, 646.	3.3	47
103	Three sample preparation protocols for polymerase chain reaction based detection of Cryptosporidium parvum in environmental samples. Journal of Microbiological Methods, 1999, 35, 65-71.	1.6	46
104	The Impact of Neuropsychological Impairment and Depression on Health-Related Quality of Life in HIV-Infection. Journal of Clinical and Experimental Neuropsychology, 2005, 27, 1-15.	1.3	46
105	Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial. PLOS Clinical Trials, 2007, 2, e13.	3.5	46
106	Retroviral diseases of the nervous system: pathogenic host response or viral gene-mediated neurovirulence?. Trends in Neurosciences, 2001, 24, 162-169.	8.6	45
107	Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and Î²â€arrestinâ€1 in monocytoid cells. FASEB Journal, 2008, 22, 786-796.	0.5	45
108	Human immunodeficiency virus type 1 genetic diversity in the nervous system: Evolutionary epiphenomenon or disease determinant?. Journal of NeuroVirology, 2005, 11, 107-128.	2.1	44

#	Article	IF	Citations
109	Quantitative Analysis of Human Endogenous Retrovirus-Wenvin Neuroinflammatory Diseases. AIDS Research and Human Retroviruses, 2006, 22, 1253-1259.	1.1	44
110	Activation of the executioner caspases-3 and -7 promotes microglial pyroptosis in models of multiple sclerosis. Journal of Neuroinflammation, 2020, 17, 253.	7.2	44
111	Long-term psychosocial sequelae of chronic physical disorders in childhood. Pediatrics, 1993, 91, 1131-6.	2.1	43
112	HIV-Related Neurological Syndromes Reduce Health-Related Quality of Life. Canadian Journal of Neurological Sciences, 2005, 32, 201-204.	0.5	41
113	Human Endogenous Retrovirus-K(II) Envelope Induction Protects Neurons during HIV/AIDS. PLoS ONE, 2014, 9, e97984.	2.5	41
114	GABA transport and neuroinflammation are coupled in multiple sclerosis: Regulation of the GABA transporter-2 by ganaxolone. Neuroscience, 2014, 273, 24-38.	2.3	41
115	HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. Aids, 2016, 30, 543-552.	2.2	41
116	Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics, 2001, 3, 145-151.	1.4	40
117	HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. Aids, 2002, 16, 1905-1914.	2.2	39
118	Lentivirus Infection Causes Neuroinflammation and Neuronal Injury in Dorsal Root Ganglia: Pathogenic Effects of STAT-1 and Inducible Nitric Oxide Synthase. Journal of Immunology, 2005, 175, 1118-1126.	0.8	39
119	CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB Journal, 2009, 23, 2928-2941.	0.5	39
120	Neurosteroidâ€mediated regulation of brain innate immunity in HIV/AIDS: DHEAâ€S suppresses neurovirulence. FASEB Journal, 2013, 27, 725-737.	0.5	39
121	RON-regulated innate immunity is protective in an animal model of multiple sclerosis. Annals of Neurology, 2005, 57, 883-895.	5.3	38
122	Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. Aids, 2016, 30, 2021-2031.	2.2	38
123	Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Annals of Neurology, 2001, 49, 650-8.	5.3	38
124	Envelope Gene-Mediated Neurovirulence in Feline Immunodeficiency Virus Infection: Induction of Matrix Metalloproteinases and Neuronal Injury. Journal of Virology, 2002, 76, 2622-2633.	3.4	37
125	Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain, 2007, 130, 2011-2023.	7.6	37
126	Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB Journal, 2011, 25, 2211-2220.	0.5	37

#	Article	IF	Citations
127	AIDS dementia complex with generalized myoclonus. Movement Disorders, 1997, 12, 593-597.	3.9	36
128	Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation. Glia, 2017, 65, 1590-1606.	4.9	36
129	HIV and Other Lentiviral Infections Cause Defects in Neutrophil Chemotaxis, Recruitment, and Cell Structure: Immunorestorative Effects of Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Immunology, 2006, 177, 6405-6414.	0.8	35
130	Feline Immunodeficiency Virus Xenoinfection: the Role of Chemokine Receptors and Envelope Diversity. Journal of Virology, 2002, 76, 3626-3636.	3.4	34
131	In Vivo Impairment of Neutrophil Recruitment during Lentivirus Infection. Journal of Immunology, 2003, 171, 4801-4808.	0.8	33
132	Anti-inflammatory role of GM1 and other gangliosides on microglia. Journal of Neuroinflammation, 2022, 19, 9.	7.2	32
133	Rabies viruses infect primary cultures of murine, feline, and human microglia and astrocytes. Archives of Virology, 1997, 142, 1011-1019.	2.1	31
134	Neuroimmune and neurovirological aspects of human immunodeficiency virus infection. Advances in Virus Research, 2001, 56, 389-433.	2.1	31
135	Encephalopathy in Liver Transplantation: Neuropathology and CMV Infection. Canadian Journal of Neurological Sciences, 1990, 17, 378-381.	0.5	30
136	Age- and Disease-Dependent HERV-W Envelope Allelic Variation in Brain: Association with Neuroimmune Gene Expression. PLoS ONE, 2011, 6, e19176.	2.5	30
137	Aberrant cortical neurogenesis in a pediatric neuroAIDS model: neurotrophic effects of growth hormone. Aids, 2005, 19, 1781-1791.	2.2	29
138	Neurobehavioral Performance in Feline Immunodeficiency Virus Infection: Integrated Analysis of Viral Burden, Neuroinflammation, and Neuronal Injury in Cortex. Journal of Neuroscience, 2009, 29, 8429-8437.	3.6	29
139	Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder. Molecular and Cellular Biology, 2015, 35, 3684-3700.	2.3	29
140	HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNAâ€“455-3p induction. JCI Insight, 2018, 3, .	5.0	28
141	Major histocompatibility complex Class I expression in oligodendrocytes induces hypomyelination in transgenic mice. Journal of Neuroscience Research, 1996, 44, 165-173.	2.9	27
142	Human Immunodeficiency Virus Type 1 Clade A and D Neurotropism: Molecular Evolution, Recombination, and Coreceptor Use. Virology, 2001, 283, 19-30.	2.4	27
143	Neurovirulence depends on virus input titer in brain in feline immunodeficiency virus infection: Evidence for activation of innate immunity and neuronal injury. Journal of NeuroVirology, 2002, 8, 420-431.	2.1	27
144	Interactions between human immunodeficiency virus (HIV)-1 Vpr expression and innate immunity influence neurovirulence. Retrovirology, 2011, 8, 44.	2.0	27

#	Article	IF	Citations
145	Cysteinyl Leukotriene Receptor Antagonists Inhibit Migration, Invasion, and Expression of MMP-2/9 in Human Glioblastoma. Cellular and Molecular Neurobiology, 2018, 38, 559-573.	3.3	27
146	RON Receptor Tyrosine Kinase, a Negative Regulator of Inflammation, Inhibits HIV-1 Transcription in Monocytes/Macrophages and Is Decreased in Brain Tissue from Patients with AIDS. Journal of Immunology, 2004, 173, 6864-6872.	0.8	26
147	Proteinase-activated receptor-1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS. Brain, 2011, 134, 3209-3221.	7.6	26
148	Lifetime antiretroviral exposure and neurocognitive impairment in HIV. Journal of NeuroVirology, 2020, 26, 743-753.	2.1	26
149	Brain-derived human immunodeficiency virus-1 Tat exerts differential effects on LTR transactivation and neuroimmune activation. Journal of NeuroVirology, 2007, 13, 173-184.	2.1	25
150	Impact of current antiretroviral therapies on neuroAIDS. Expert Review of Anti-Infective Therapy, 2011, 9, 371-374.	4.4	25
151	Delineating HIV-Associated Neurocognitive Disorders Using Transgenic Models: The Neuropathogenic Actions of Vpr. Journal of NeuroImmune Pharmacology, 2012, 7, 319-331.	4.1	25
152	Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. Journal of NeuroVirology, 2004, 10, 113-117.	2.1	24
153	HIV-1 Nef expression in microglia disrupts dopaminergic and immune functions with associated mania-like behaviors. Brain, Behavior, and Immunity, 2014, 40, 74-84.	4.1	24
154	Neurocognitive Symptoms and Impairment in an HIV Community Clinic. Canadian Journal of Neurological Sciences, 2001, 28, 228-231.	0.5	23
155	Fibroblast Growth Factor 2 Enhances Zika Virus Infection in Human Fetal Brain. Journal of Infectious Diseases, 2019, 220, 1377-1387.	4.0	23
156	Nerve growth factor acts through the TrkA receptor to protect sensory neurons from the damaging effects of the HIV-1 viral protein, Vpr. Neuroscience, 2013, 252, 512-525.	2.3	22
157	The brain and HAART. Current Opinion in HIV and AIDS, 2014, 9, 579-584.	3.8	22
158	HIV-1 persistence in the central nervous system: viral and host determinants during antiretroviral therapy. Current Opinion in Virology, 2019, 38, 54-62.	5.4	22
159	Interplay between Zika Virus and Peroxisomes during Infection. Cells, 2019, 8, 725.	4.1	22
160	Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS. Canadian Journal of Psychiatry, 2018, 63, 329-336.	1.9	21
161	Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. Journal of NeuroVirology, 2004, 10, 113-117.	2.1	20
162	Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. Aids, 2006, 20, 2005-2009.	2.2	20

#	Article	IF	Citations
163	Regulation of eotaxinâ€3/CCL26 expression in human monocytic cells. Immunology, 2010, 130, 74-82.	4.4	20
164	Neuromyelitis Optica With Extensive Active Brain Involvement. Archives of Neurology, 2011, 68, 508.	4.5	20
165	CD8+ Lymphocyte-Mediated Injury of Dorsal Root Ganglion Neurons during Lentivirus Infection: CD154-Dependent Cell Contact Neurotoxicity. Journal of Neuroscience, 2006, 26, 3396-3403.	3.6	19
166	Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation. MBio, 2021, 12, e0278421.	4.1	19
167	Xenoinfection of nonhuman primates by feline immunodeficiency virus. Current Biology, 2001, 11, 1109-1113.	3.9	18
168	Differential type 1 interferonâ€regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence. FASEB Journal, 2013, 27, 2829-2844.	0.5	18
169	The HIV-1 Accessory Protein Vpu Downregulates Peroxisome Biogenesis. MBio, 2020, 11, .	4.1	18
170	Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period. Aids, 2021, 35, 63-72.	2.2	17
171	Dehydroepiandrosterone sulphate improves cholestasisâ€associated fatigue in bile duct ligated rats. Neurogastroenterology and Motility, 2009, 21, 1319-1325.	3.0	16
172	Absent in melanoma 2 regulates tumor cell proliferation in glioblastoma multiforme. Journal of Neuro-Oncology, 2019, 144, 265-273.	2.9	16
173	Empiric neurocognitive performance profile discovery and interpretation in HIV infection. Journal of NeuroVirology, 2019, 25, 72-84.	2.1	16
174	Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS. Journal of NeuroVirology, 2020, 26, 41-51.	2.1	16
175	Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. BMC Neurology, 2010, 10, 44.	1.8	15
176	Regulation of Lentivirus Neurovirulence by Lipopolysaccharide Conditioning: Suppression of CXCL10 in the Brain by IL-10. Journal of Immunology, 2010, 184, 1566-1574.	0.8	15
177	Metagenomic and Metabolomic Characterization of Rabies Encephalitis: New Insights into the Treatment of an Ancient Disease. Journal of Infectious Diseases, 2013, 207, 1451-1456.	4.0	15
178	Neuroinflammation Preceding and Accompanying Primary Central Nervous System Lymphoma: Case Study and Literature Review. World Neurosurgery, 2016, 88, 692.e1-692.e8.	1.3	15
179	Human pegivirusâ€1 associated leukoencephalitis: Clinical and molecular features. Annals of Neurology, 2018, 84, 781-787.	5.3	15
180	Neurologic disease in feline immunodeficiency virus infection: disease mechanisms and therapeutic interventions for NeuroAIDS. Journal of NeuroVirology, 2018, 24, 220-228.	2.1	14

#	Article	IF	Citations
181	Human immunodeficiency virus type 1 envelope-mediated neuropathogenesis: targeted gene delivery by a Sindbis virus expression vector. Virology, 2003, 309, 61-74.	2.4	13
182	NeuroAIDS in West Africa: A Full Circle. Canadian Journal of Neurological Sciences, 2007, 34, 118-119.	0.5	13
183	Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability. BMC Neurology, 2015, 15, 61.	1.8	13
184	Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). Journal of Clinical and Experimental Neuropsychology, 2015, 37, 733-750.	1.3	13
185	Modulation of NKG2D-Mediated Cytotoxic Functions of Natural Killer Cells by Viral Protein R from HIV-1 Primary Isolates. Journal of Virology, 2011, 85, 12254-12261.	3.4	12
186	The Regulation of Reactive Changes Around Multiple Sclerosis Lesions by Phosphorylated Signal Transducer and Activator of Transcription. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1135-1144.	1.7	12
187	Encephalopathy with Staphylococcal Endocarditis: Multiple Neuropathological Findings. Canadian Journal of Neurological Sciences, 2001, 28, 260-264.	0.5	11
188	The Human Microbiome in Multiple Sclerosis: Pathogenic or Protective Constituents?. Canadian Journal of Neurological Sciences, 2010, 37, S24-S33.	0.5	11
189	Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors. Canadian Journal of Neurological Sciences, 2016, 43, 157-162.	0.5	11
190	HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. Cell Death and Differentiation, 2019, 26, 1942-1954.	11.2	11
191	Lentivirus envelope protein exerts differential neuropathogenic effects depending on the site of expression and target cell. Virology, 2006, 348, 260-276.	2.4	10
192	Intranasal antiâ€caspaseâ€1 therapy preserves myelin and glucose metabolism in a model of progressive multiple sclerosis. Glia, 2021, 69, 216-229.	4.9	10
193	NeuroAIDS: a watershed for mental health and nervous system disorders. Journal of Psychiatry and Neuroscience, 2009, 34, 83-5.	2.4	10
194	Antisense Oligodeoxynucleotides Targeting Internal Exon Sequences Efficiently Regulate TNF-Î± Expression. Oligonucleotides, 1999, 9, 135-144.	4.3	9
195	Targeted Elimination of Peroxisomes During Viral Infection: Lessons from HIV and Other Viruses. DNA and Cell Biology, 2018, 37, 417-421.	1.9	9
196	Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 2021, 65, e0049121.	3.2	9
197	Determinants of risk-taking in HIV-associated neurocognitive disorders.. Neuropsychology, 2017, 31, 798-810.	1.3	8
198	Dual lentivirus infection potentiates neuroinflammation and neurodegeneration: viral copassage enhances neurovirulence. Journal of NeuroVirology, 2009, 15, 139-152.	2.1	7

#	Article	IF	Citations
199	Modeling brain lentiviral infections during antiretroviral therapy in AIDS. Journal of NeuroVirology, 2017, 23, 577-586.	2.1	7
200	Infection of Glia by Human Pegivirus Suppresses Peroxisomal and Antiviral Signaling Pathways. Journal of Virology, 2021, 95, e0107421.	3.4	7
201	Use of Primary Human Fetal Astrocytes and Tissue Explants as Ex Vivo Models to Study Zika Virus Infection of the Developing Brain. Methods in Molecular Biology, 2020, 2142, 251-259.	0.9	7
202	Modeling the Effects of Latency Reversing Drugs During HIV-1 and SIV Brain Infection with Implications for the â€œShock and Killâ€•Strategy. Bulletin of Mathematical Biology, 2021, 83, 39.	1.9	5
203	Progressive multifocal leukoencephalopathy and Creutzfeldt-Jakob disease: population-wide incidences, comorbidities, costs of care, and outcomes. Journal of NeuroVirology, 2021, 27, 476-481.	2.1	5
204	Application of â€œOmicsâ€•Technologies for Diagnosis and Pathogenesis of Neurological Infections. Current Neurology and Neuroscience Reports, 2015, 15, 58.	4.2	4
205	Predictive variables for peripheral neuropathy in treated HIV type 1 infection revealed by machine learning. Aids, 2021, 35, 1785-1793.	2.2	4
206	Differential disease phenotypes and progression in relapsingâ€“remitting multiple sclerosis: comparative analyses of single Canadian and Saudi Arabian clinics. BMC Neurology, 2021, 21, 295.	1.8	4
207	Intracellular nickel accumulation induces apoptosis and cell cycle arrest in human astrocytic cells. Metallomics, 2021, 13, .	2.4	4
208	Interactions of the human immunodeficiency virus with astrocytes. Journal of Computer - Aided Molecular Design, 1996, 5, 30-42.	1.0	3
209	A neuropathic pain syndrome associated with hantavirus infection. Journal of NeuroVirology, 2017, 23, 919-921.	2.1	3
210	Sarcocystis myopathy in a patient with HIV-AIDS. Journal of NeuroVirology, 2018, 24, 376-378.	2.1	3
211	Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile. Neurological Sciences, 2021, 42, 5241-5247.	1.9	3
212	Long-term consequences of interpersonal violence experiences on treatment engagement and health status in people living with HIV. Aids, 2021, 35, 801-809.	2.2	3
213	Central Nervous System Viral Infections: Clinical Aspects and Pathogenic Mechanisms. , 2007, , 485-499.		2
214	Emerging Issues in Neurovirology: New Viruses, Diagnostic Tools, and Therapeutics. Neurologic Clinics, 2008, 26, 855-864.	1.8	2
215	Reply to Dr. Garson and Colleagues. AIDS Research and Human Retroviruses, 2009, 25, 379-381.	1.1	2
216	Domain- and nucleotide-specific Rev response element regulation of feline immunodeficiency virus production. Virology, 2010, 404, 246-260.	2.4	2

#	Article	IF	Citations
217	Multifocal inflammatory demyelination in a patient with rheumatoid arthritis and treatment complications. Journal of the Neurological Sciences, 2016, 367, 305-307.	0.6	2
218	Immune Sensors and Effectors of Health and Disease. , 2017, , 93-105.		2
219	Tumor-to-Lesion Metastasis: Case Report of Carcinoma Metastasis to Multiple Sclerosis Lesion. World Neurosurgery, 2018, 116, 14-17.	1.3	2
220	Proteinase-activated receptor expression and function in the brain. Drug Development Research, 2003, 60, 51-57.	2.9	1
221	Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. Journal of NeuroVirology, 2004, 10, 113-117.	2.1	1
222	NEUROLOGICAL DISORDERS ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION. , 2007, , 1261-1272.		1
223	Neuro-inflammation. , 0, , 245-260.		1
224	Closing in on an infectious etiology of motor neuron disease. Neurology, 2016, 87, 1750-1751.	1.1	1
225	Rapid Multifocal Neurologic Decline in an Immunocompromised Patient. JAMA Neurology, 2016, 73, 226.	9.0	1
226	Neurocognitive Impairment and Associated Genetic Aspects in HIV Infection. Current Topics in Behavioral Neurosciences, 2018, 50, 41-76.	1.7	1
227	Sparse Multicategory Generalized Distance Weighted Discrimination in Ultra-High Dimensions. Entropy, 2020, 22, 1257.	2.2	1
228	Plasma microRNAs are associated with domain-specific cognitive function in people with HIV. Aids, 2021, 35, 1795-1804.	2.2	1
229	Chemokine Proteolytic Processing in HIV Infection: Neurotoxic and Neuroimmune Consequences. , 2010, , 149-172.		1
230	Viral and Host Genetic Factors. , 2011, , 50-70.		1
231	Preface. Neurologic Clinics, 2008, 26, xiii-xv.	1.8	0
232	NEUROLOGIC IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV/AIDS: OUTCOME AND EPIDEMIOLOGY. Neurology, 2009, 73, 2046-2047.	1.1	0
233	Editorial. Current Opinion in HIV and AIDS, 2014, 9, 515-516.	3.8	0
234	Misinterpretation of Study Data. JAMA Neurology, 2019, 76, 113.	9.0	0

#	Article	IF	Citations
235	HIV-1 Infection and Cell Death in the Nervous System. , 2005, , 381-403.		0